Latest Interviews
Showing 1–2 of 2 transcripts.
Clear all filters- a16z21 min
AI is Industrializing Discovery
The speaker characterizes the current biotech era as an industrial revolution where AI is transforming drug discovery from a bespoke artisanal model into a scalable, engineering-driven process. By overcoming myths regarding biological complexity and data scarcity through techniques like graph convolutions and one-shot learning, companies are achieving accuracy rates of over 90% in biomarker discovery and predicting clinical outcomes with modest incremental gains. This strategic shift promises to slash manufacturing costs for protein therapeutics by up to 90% and reduce trial expenses, creating a critical opportunity for professionals to merge domain expertise with AI skills to industrialize discovery at unprecedented scale.
- a16z14 min
a16z Podcast | The Genetics Of Drug Delivery
Stanford professor Russ Altman leads a data science laboratory that integrates molecular, cellular, and population-level data to optimize drug response and identify previously unknown side effects. By analyzing diverse sources ranging from electronic medical records to web search logs, Altman's team successfully uncovered critical interactions, such as a glucose spike caused by combining paroxetine and pravastatin, and predicted new therapeutic uses for existing cancer drugs. This multi-scale approach, supported by funding from the National Institutes of Health and industry partners like Pfizer and Genentech, aims to replace fragmented clinical trial models with continuous, data-driven surveillance for safer and more effective pharmaceutical development.